Clinical evaluations of .BETA.2-microglobulin adsorbing Lixelle columns; S-15 and S-35. A multi-center study.

Gejyo, Fumitake; Amano, Izumi; Nakazawa, Ryoichi; Anzai, Takayuki; Itami, Noritomo; Inoue, Seishi; Obayashi, Seiichi; Ohira, Suguru; Oyabu, Yasuhiko; Ono, Toshihiko; Kato, Yoshikazu; Kanno, Yutaka; Kim, Masao; Kobayashi, Takeshi; Kondo, Morihiro; Sato, Motoyoshi; Shin, Jeongsoo; Suzuki, Masashi; Seno, Hachiro; Takahashi, Susumu; Taguma, Toshio; Takemoto, Yoshiaki; Tsutsui, Shuichi; Nakayama, Shinji; Hatta, Hideo; Hyodo, Toru; Matsushima, T; Motomiya, Yoshihiro; Morita, Hiroyuki; Kawaguchi, Yoshiya

doi:10.4009/jsdt.36.117

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was reported that S‐15 showed a similar efficacy to S‐35 inrelieving joint pain when used for 6 months (18). Because Lixelle S‐15 is still new to the market, evaluation of long‐termclinical data is still underway.…”

Section: Clinical Applicationsmentioning

confidence: 96%

“…The performanceof Lixelle S‐15 in clinical use depends on the kinds of dialysismembranes used concomitantly. The total amount of β 2 ‐meliminated using S‐15 was more than 90% of the total amount eliminatedusing S‐35, in combination with a dialysis membrane with a β 2 ‐mclearance of 50 mL/min or higher (18).…”

Section: Clinical Applicationsmentioning

confidence: 99%

“…Lixelle S‐15 was developed to reduce extracorporeal volume soas to decrease the incidence of such adverse effects. In addition,the residual blood in the adsorption column was also decreased.It has been reported that the incidence of adverse effects of S‐15 usewas about one‐third of that of S‐35 (18). Evaluation of the factors that reduce adverse effects of LixelleS‐15 is in progress.…”

Section: Adverse Effectsmentioning

confidence: 99%

See 2 more Smart Citations

β₂‐Microglobulin‐selective AdsorbentColumn (Lixelle) for the Treatment of Dialysis‐related Amyloidosis

Suzuki¹,

Shimazaki²,

Kutsuki³

2003

Ther Apher Dial

View full text Add to dashboard Cite

Lixelle is a direct hemoperfusion-type adsorbent column developed for selective elimination of beta2-microglobulin (beta2-m) from the circulating blood of patients with dialysis-related amyloidosis (DRA). Lixelle S-35, that has a column volume of 350 mL, efficiently eliminates beta2-m and improves symptoms of DRA such as joint pain and nocturnal awakening. The performance of Lixelle S-15, that has a column volume of 150 mL, is dependent on the dialysis membrane used in combination with the adsorbent column in a hemodialysis circuit. The combination of S-15 and a dialysis membrane with a high beta2-m clearance eliminates an amount of beta2-m that is nearly equal to the amount removed by using S-35. Treatment with S-15 for 6 months improved joint pain with an efficacy similar to that observed when using S-35. The major adverse effects were hypotension and decrease in hematocrit, and these incidences were much less in S-15 compared to S-35.

show abstract

Section: Clinical Applicationsmentioning

confidence: 96%

Section: Clinical Applicationsmentioning

confidence: 99%

Section: Adverse Effectsmentioning

confidence: 99%

See 1 more Smart Citation

β₂‐Microglobulin‐selective AdsorbentColumn (Lixelle) for the Treatment of Dialysis‐related Amyloidosis

Suzuki¹,

Shimazaki²,

Kutsuki³

2003

Ther Apher Dial

View full text Add to dashboard Cite

show abstract

“…Two types of column were used: the S-15 with 150 ml and S-35 with 350 ml column volumes. The S-15 column was used for patients unable to tolerate the S-35 column because of its larger extracorporeal blood volume [7]. …”

Section: Methodsmentioning

confidence: 99%

Effectiveness of β<sub>2</sub>-Microglobulin Adsorption Column in Treating Dialysis-Related Amyloidosis: A Multicenter Study

Kuragano

Inoue

Shin³

et al. 2011

Blood Purif

Self Cite

View full text Add to dashboard Cite

Background/Aims: The aim of this study was to determine whether treatment with β₂-microglobulin adsorption column (Lixelle) affects bone cysts and clinical symptoms in patients with dialysis-related amyloidosis (DRA). Methods: Radiographic changes in the number and area of bone cysts of the wrist and the hip joint were compared between 39 hemodialysis (HD) patients treated with Lixelle (Lixelle group) and 28 HD patients treated with conventional therapy as retrospective control (HD group). Clinical symptoms of DRA were also evaluated. Results: In the Lixelle group, the number of bone cysts and the cystic area in wrist joints were significantly decreased, although the changes in these parameters in hip joints were not significant. In the HD group, the corresponding parameters in the hip joints even significantly increased. Clinical symptoms notably improved after Lixelle treatment. Conclusion: Treatment with Lixelle reduces the radiolucency of bone cysts in the wrist joints, and improves clinical symptoms associated with DRA.

show abstract

β2-Microglobulin-selective direct hemoperfusion column for the treatment of dialysis-related amyloidosis

Kutsuki

2005

Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics

View full text Add to dashboard Cite

Clinical evaluations of .BETA.2-microglobulin adsorbing Lixelle columns; S-15 and S-35. A multi-center study.

Cited by 3 publications

References 0 publications

β₂‐Microglobulin‐selective AdsorbentColumn (Lixelle) for the Treatment of Dialysis‐related Amyloidosis

β₂‐Microglobulin‐selective AdsorbentColumn (Lixelle) for the Treatment of Dialysis‐related Amyloidosis

Effectiveness of β<sub>2</sub>-Microglobulin Adsorption Column in Treating Dialysis-Related Amyloidosis: A Multicenter Study

β2-Microglobulin-selective direct hemoperfusion column for the treatment of dialysis-related amyloidosis

Contact Info

Product

Resources

About

Clinical evaluations of .BETA.2-microglobulin adsorbing Lixelle columns; S-15 and S-35. A multi-center study.

Cited by 3 publications

References 0 publications

β2‐Microglobulin‐selective AdsorbentColumn (Lixelle) for the Treatment of Dialysis‐related Amyloidosis

β2‐Microglobulin‐selective AdsorbentColumn (Lixelle) for the Treatment of Dialysis‐related Amyloidosis

Effectiveness of β<sub>2</sub>-Microglobulin Adsorption Column in Treating Dialysis-Related Amyloidosis: A Multicenter Study

β2-Microglobulin-selective direct hemoperfusion column for the treatment of dialysis-related amyloidosis

Contact Info

Product

Resources

About

β₂‐Microglobulin‐selective AdsorbentColumn (Lixelle) for the Treatment of Dialysis‐related Amyloidosis

β₂‐Microglobulin‐selective AdsorbentColumn (Lixelle) for the Treatment of Dialysis‐related Amyloidosis